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ABSTRACT

Primitive or progenitor hematologic cancer cells have been

implicated in the early stages and development of leukemia
and malignant lymphoproliferative disorders, including acute
myelogenous leukemia (AML), chronic myelogenous leuke
mia (CML) and chronic lymphoid leukemia (CLL). Interleu
kin-3 receptor alpha chain (IL-3Ra or CD123) is strongly
expressed on progenitor hematologic cancer cells, but is vir
tually undetectable on normal bone marrow cells. The present

invention provides methods of impairing progenitor hemato
logic cancer (e.g., leukemia and lymphomic) cells by selec
tively targeting cells expressing CD123. These methods are
useful in the detection and treatment of leukemias and malig
nant lymphoproliferative disorders. Also provided are com
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pounds useful for selectively binding to CD123 and impairing
progenitor hematologic cancer cells. These compounds may
include cytotoxic moieties such as, for example, radioiso
topes or chemotherapeutics.

10 Claims, 8 Drawing Sheets

US. Patent

Oct. 7, 2014

US 8,852,551 B2

Sheet 2 0f 8

co...
.2
N2
“2
B.

dOE.on eE

,ol‘l 01 ;Ol 00
OdV-BQUO

@5480

#2.28
’1 011 lol 00
Hd-QZ lOQ

US. Patent

0a. 7, 2014

Sheet 3 0f8

US 8,852,551 B2

cow/cuss
8

I

E

J

i

m

1

FIG.2A

D

8
O

5

10°

101

o

1o2

CD123—PE

103

1o4

cos4+/coaa

N

l

E

J

I

m

'

FIG.2B

D

8
o

‘

10°
g

10'
I

E
8

1o2

CD123—PE

1o4

coa4+/cnaa

Y

2)

103

M1

FIG.2C

C

10°

10'

102

CDIZIS-PE

103

1o4

wan/cow
FIG.2D

FIG.2E

U S. Patent

Oct. 7, 2014

Tut.

6:52 +30

Sheet 5 0f 8

AML CD34+

FIG.4

US 8,852,551 B2

US. Patent

0a. 7, 2014

anti-Mark V

Sheet 6 0f8

' lantiP-Mek

FIG.5C

US 8,852,551 B2

US. Patent

Oct. 7, 2014

Sheet 7 0f8

US 8,852,551 B2

CD123 EXPRESSION IN PRIMARY ALL

é,

a;

COUNTS 3%
Si?

,

o»:

’

1o0

_

.

10'

5'

1o2

103

104

00123 PE

F=IC3.€5/\
c0123 EXPRESSION IN PRIMARY ALI.

g5;
53 ,

g

COUNTS 5

3100

10'

102

103

104

00123 PE

F:l(5.€5E3
00123 EXPRESSION IN PRIMARY ALL
5;

,

N:

53%

COUNTS 8%8%
03

>

100

10"

102
00123 PE

IZIC5.€5(Z

103

US. Patent

0a. 7, 2014

Sheet 8 0f8

US 8,852,551 B2

CD123 EXPRESSION lN PRIMARY CML

§55
8

g l"
5 s,
3‘

.

10°

101

102

1o3

104

CD123—PE

F=IC5.77/\
00123 EXPRESSION IN PRIMARY cm.

55:

£5
23 i
5?.

10°

_

10'

102

1o3

104

CD123—PE

F=|C5.17E3
00123 EXPRESSION IN PRIMARY cm.

8

N

g5 ~
8

1

5??
c,.

100

com-PE

IZIC5.]7(I

US 8,852,551 B2
1

2

METHODS TO IMPAIR HEMATOLOGIC
CANCER PROGENITOR CELLS AND
COMPOUNDS RELATED THERETO

are often of clonal origin and display relatively homogeneous
features, it has been demonstrated that such populations are
organized in a hierarchical fashion, analogous to normal

hematopoietic progenitors. Thus, there is a phenotypically
CONTINUING DATA

de?ned leukemic stem cell population that is suf?cient to
propagate leukemic blasts both in vitro and in vivo in xeno

The present application is a continuation of US. applica
tion Ser. No. 10/830,089, ?led Apr. 23, 2004, now US. Pat.
No. 7,651,678, which is a continuation of US. application
Ser. No. 09/799,100, ?led Mar. 6, 2001, now US. Pat. No.
6,733,743, which claims the bene?t of priority to US. Pro
visional Patent Application Nos. 60/187,123, ?led Mar. 6,

geneic mouse models of human AML (Bonnet D, et al.,
Human acute myeloid leukemia is organized as a hierarchy
that originates from a primitive hematopoietic cell. Nat. Med.
1997, 3: 730-737; Blair A, et al., Most acute myeloid leuke

mia progenitor cells with long-term proliferative ability in

2000, and 60/227,295, ?ledAug. 24, 2000, the disclosures of
each of which are incorporated by reference herein in their

entirety.
BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention is related to methods of impairing
progenitor hematologic cancer cells or treating hematologic
cancer by targeting a cell surface marker speci?c for progeni
tor hematologic cancer cells. The present invention is also

20

stem cell (LSC) becomes critically important in considering
the etiology of human disease. Clearly, in order to achieve
durable remission, it will be necessary to speci?cally ablate

related to a method for diagnosing hematologic cancer.

2. Background of the Invention

the primitive or progenitor LSC population. However, previ
25

Stem cells are commonly found in a variety of mammalian
tissue systems. While the criteria by which such cells are

1944-50), as well as data from our group, suggest that LSC’s
are biologically distinct from more mature leukemic blasts

erties are generally regarded as central features of stem cell
30

capable of differentiating into appropriate lineages (Potten C
S: Stem Cells. London, Academic Press, 1997). Cells of this
nature have been described for a number of tissues including

hematopoietic, embryonic, neural, muscle and hepatic sys
tems (Lemischka I R. Clonal, in vivo behavior of the totipo
tent hematopoietic stem cell. Semin Immunol 1991, 3: 349
55; Morrison S J, et al., The biology of hematopoietic stem
cells.Annu. Rev. Cell Dev. Biol. 1995, 11: 35-71; Robertson
E 1., Using embryonic stem cells to introduce mutations into
the mouse germ line. Biol Reprod 1991, 44: 238-45; Gage F
H., Mammalian neural stem cells. Science 2000, 287: 1433-8;
and, Alison M, et al., Hepatic stem cells. J Hepatal 1998, 29:
676-82). Thus, it is perhaps not surprising that similar cells
have recently been documented in the context of malignant

35

1007-13). Indeed, a stem cell is in some respects the ideal

1997, 14: 53-60). If LSC’s are more refractile to chemo
40

cells may provide more effective treatment for leukemia

patients. In 1997, Bonnet and Dick described the phenotype
for LSC’s as CD34+/CD38— (Bonnet D, et al., Human acute
45

50

hematopoietic cells. In view of this state of the art, there is a
need in the art to provide a diagnostic method for detecting
leukemia at an early stage, as well as more effective methods

SUMMARY OF THE INVENTION
55

The present invention relates to a method of using com

pounds that bind to the human CD123 molecule (CD123
ectopeptide), in the diagnosis and treatment of hematologic
cancers (e.g., leukemias and malignant lymphoproliferative
60

disease.

One example of neoplasia arising from malignant stem

disorders). The CD123 speci?c compounds and mimetics
have particular utility as pharmaceuticals and reagents for the
therapy of hematologic cancer or malignant disease states and
for the diagnosis of hematologic cancer disease states. In one
embodiment, the present invention provides a method of

cells has recently been documented in the hematopoietic sys
tem in the case of acute myelogenous leukemia (AML). This

non-functional leukemic blasts. While leukemic blast cells

myeloid leukemia is organized as a hierarchy that originates
from a primitive hematopoietic cell. Nat. Med. 1997, 3: 730
737). We report that the IL-3 receptor alpha chain (CD123) is
highly expressed on leukemic but not normal CD34+/CD38—

of treating this disease.

erative and developmentally plastic, one can imagine that

disease is characterized by premature arrest of myeloid devel
opment and the subsequent accumulation of large numbers of

stem cells are a major contributing factor to leukemic relapse.

Thus, strategies that speci?cally target progenitor leukemia

target for malignant transformation in that relatively little
biological change is required. Since stem cells already pos
sess the genetic programming necessary to be highly prolif
relatively subtle perturbations might be suf?cient to induce

and may not be responsive to conventional chemotherapeutic
regimens. This observation is consistent with the clinical
pro?le frequently seen for AML, wherein a majority of
patients can achieve apparent complete remission, but in most
cases will relapse (Schiller G 1., Treatment of resistant dis
ease. Leukemia 1998, 12 Suppl 1: S20-4; Paietta E., Classical
multidrug resistance in acute myeloid leukemia. Med Oncol

therapy than blasts, it is attractive to propose that surviving

populations (Bonnet D, et al., Human acute myeloid leukemia
is organized as a hierarchy that originates from a primitive
hematopoietic cell. Nat. Med. 1997, 3: 730-737; Blair A, et
al., Most acute myeloid leukemia progenitor cells with long
term proliferative ability in vitro and in vivo have the pheno
type CD34(+)/CD71(—)/HLA-DR—. Blood 1998, 92: 4325
35; Cobaleda C, et al., A primitive hematopoietic cell is the
target for the leukemic transformation in human Philadel
phia-positive acute lymphoblastic leukemia. Blood 2000, 95:

ous studies (Terpstra W, et al., Fluorouracil selectively spares
acute myeloid leukemia cells with long-term growth abilities
in immunode?cient mice and in culture. Blood 1996, 88:

de?ned vary depending upon the speci?c context, two prop
populations: (1) stem cells must exhibit some capacity for
self-replication or self-renewal, and (2) stem cells must be

vitro and in vivo have the phenotype CD34(+)/CD71(—)/
HLA-DR—. Blood 1998, 92: 4325-35, Cobaleda C, et al., A
primitive hematopoietic cell is the target for the leukemic
transformation in human Philadelphia-positive acute lym
phoblastic leukemia. Blood 2000, 95: 1007-13; BlairA, et al.
Lack of expression of Thy-1 (CD90) on acute myeloid leu
kemia cells with long-term proliferative ability in vitro and in
vivo. Blood 1997, 89: 3104-12). The concept ofa leukemic

65

impairing a hematologic cancer progenitor cell comprising
contacting the cell with a compound that selectively binds to
CD 1 23 in an amount effective to impair the progenitor hema

US 8,852,551 B2
3

4

tologic cancer cell. This contacting step may occur in various
environments, including in vitro and in vivo in the body of an
animal, including a human.

accompanying drawings which are given by way of illustra
tion only, and thus are not limiting of the present invention,
and wherein:
FIGS. 1A and 1B show CD123 expression on normal and

Throughout this application, reference will be made spe
ci?cally to leukemia in describing certain embodiments of the
present invention. However, it is understood that the present

leukemic hematopoietic cells. Representative examples of
CD123 labeling in cells derived from normal bone marrow

(panel A) or primary AML peripheral blood (panel B) are
provided. The inset polygon in panel A (left dot plot) indicates

invention is not limited to diagnosis and treatment of leuke

mia or malignant lymphoproliferative disorders alone, but to

the percentage of total bone marrow that is positive for

any disease in which the cancerous cells selectively express
CD123, which includes the genus of hematologic cancer.
In one embodiment, the present invention is directed to a

CD123 expression (7%). The smaller rectangular gate indi
cates the proportion of total marrow strongly positive for
CD123 (1%). The center dot plot in panel A shows bone

method of detecting the presence of CD123 on, for example,
a leukemia progenitor cell. Thus, the invention is also directed
to a method of diagnosing leukemia. It is understood that by
using a labeled ligand to bind to CD123, it is possible to detect
the presence of leukemia progenitor cells. Thus, it is also
possible to diagnose the likelihood of the onset of leukemia in

marrow that was enriched for CD34+ cells by selection on an

patients possessing such leukemic progenitor cells express
ing CD123. The CD123 binding ligand may be an antibody to

20

analyzed.

CD123, or it may be any of a variety of molecules that spe
ci?cally bind to CD123. Furthermore, the label can be chosen

FIG. 2 shows CD expression on ?ve primitive AML popu
lations. Five primary AML specimens were labeled with

from any of a variety of molecules, including, but not limited

to, enzymatic compounds, or non-enzymatic compounds that
serve as a reporter of the presence of the ligand which has

25

bound to the CD123 molecule. Examples of such labels

include those that are, for example, radioactive, ?uorescent,
chemiluminescent or absorbant-based, or a combination of

the foregoing. In one embodiment, an assay is provided for
detecting the presence of progenitor leukemia cells in a

30

CD34, CD38, and CD123 and analyzed by ?ow cytometry.
The ?gure shows CD123 labeling for the CD34+/CD38—
gated populations from each sample. The dark sections indi
cate CD123 staining and the light sections indicate parallel
labeling with an isotype control antibody. M1 markers in the
histograms indicate expression levels that are higher than
99% of isotype control samples. For each specimen, 50,000
100,000 events were analyzed.

sample by detecting the presence of CD123 in the sample,
which may be accomplished by introducing a compound that
selectively binds to CD123 and determining whether the
compound binds to a component of the sample.
In another series of embodiments, the present invention
also provides compounds or molecules which mimic (mimet

immunoaf?nity column (see methods). The gates indicate the
total CD34+ population and the CD34+/CD38— population.
The histograms indicate the CD123 labeling for the two gated
populations. Panel B shows the same analysis for the primary
AML specimen. M1 markers in the histograms indicate
expression levels that are higher than 99% of isotype control
samples. For each specimen, 50,000-100,000 events were

FIGS. 3A and 3B show engraftment of CD123+ AML cells
in NOD/SCID mice. Sorted CD34+/CD123+ primary AML
35

cells were transplanted into an irradiated NOD/SCID mouse.
Six weeks post-transplant, bone marrow cells were isolated

and analyzed for the presence of human (CD45+) leukemic
cells. Panel A shows the CD34 vs. CD45 pro?le of an

ics) the three-dimensional structure of part or all of the com

engrafted specimen using antibodies that are speci?c to

pounds such as peptides, antibodies, carbohydrates, lipids or

human cells. Panel B shows the CD34 vs. CD123 pro?le of

nucleic acids that bind to CD123, and in the case of antibod

40

ies, of the binding pockets of the antibodies, or of the comple

50,000 events were analyzed.
FIG. 4 shows CD123 and CD131 immunoblot analysis of

mentarity determining regions (CDR’s).

primary AML specimens. Five primary AML samples were

The present invention also provides pharmaceutical prepa
rations comprising a pharmaceutically acceptable carrier; and
any one or more of the CD123 speci?c compounds and

45

mimetics described above.
In another set of embodiments, the present invention pro
vides a method for the treatment of leukemia, comprising
administering to a human subject or other animal in need of
such treatment a therapeutically effective amount of the com

50

55

AML samples (Lanes 1-3) were derived from peripheral

60

electro-blotted and membranes were probed with antibodies

speci?c to either total or phosphorylated protein for Akt (A),
Stat5 (B), and Mek-1 (C). The lane labeled C on each blot is an
antibody control and is derived from NIH 3T3 cells treated
+/—50 ng/ml PDGF (A and C), or TF-1 cells treated +/—25

marrow.

BRIEF DESCRIPTION OF THE DRAWINGS
65

from the detailed description given herein below, and the

FIGS. 5A, 5B and 5C show phosphorylation of signal
transduction components in response to IL-3. Three primary
blood and sorted to isolate the CD34+ population. Samples
were treated with (+) or without (—) 20 ng/ml IL-3 for 15
minutes, then lysed and subj ected to PAGE. Each gel was then

that may be contacted to either a bone marrow sample or

The present invention will become more fully understood

to denaturing PAGE and analyzed by immunoblot with an
anti-CD123 antibody (top panel) or an anti-CD131 antibody
(bottom panel). The arrowhead at the left of each panel indi
cates the position of the IL-3RO. (CD123) and IL-3R[3

(CD 1 3 1) chains, respectively.

mia progenitor cells, or they may be the progenitor cells,
which may be impaired by the method of the invention using
various compounds or their mimetics and cytotoxic agents
injected into a bone marrow of an individual, thereby destroy
ing at least some of the leukemic stem cells in the bone

derived from peripheral blood and sorted to isolate the
CD34+ population, thus insuring a virtually pure leukemic
sample. In addition, the leukemic cell line TF-1 (TF-1) and
normal marrow CD34+ cells (normal CD34+) were included
as controls. Lysates were made from each population, subject

pounds or their mimetic pharmaceutical compositions
described above.
In still another set of embodiments, the present invention
provides a method of selectively purging leukemic stem cells
from bone marrow. These stems cells may give rise to leuke

the CD45+ gated human cell population. For each sample,

ng/ml GM-SCF (B).
FIGS. 6A, 6B and 6C show CD123 expression in primary
ALL. Flow cytometric analysis of CD123 expression on three

US 8,852,551 B2
6

5
independent primary ALL (acute lymphoid leukemia) speci

phoid. Thus, certain forms of leukemia may be, by way of

mens. CD123 labeling is shown by the ?lled (dark) plots and
controls are shown by open plots.
FIGS. 7A, 7B and 7C show CD123 expression in primary
CML. Flow cytometric analysis of CD123 expression on

example, acute lymphatic (or lymphoblastic) leukemia
(ALL); acute myelogenic leukemia (AML); chronic lympho

three independent primary CML (chronic myelogenous leu
kemia) specimens. CD123 labeling is shown by the ?lled

phoproliferative disorders” may refer to a lymphoma, such as

cytic leukemia (CLL); or chronic myelogenic leukemia

(CML); and myelodysplastic syndrome. “Malignant lym
multiple myeloma, non-Hodgkin’s lymphoma, Burkitt’s
lymphoma, and follicular lymphoma (small cell and large

(dark) plots and controls are shown by open plots.

cell), among others. For purposes of this invention, at least
DETAILED DESCRIPTION OF THE INVENTION

some of the hematologic cancer cells are characterized by

cells that express CD123.Also, for the purposes of this appli
cation, whenever leukemia or malignant lymphoproliferative
disorders are mentioned, the diagnostic and treatment method
of the invention applies generally to hematologic cancer.
As used herein, the term “introducing” shall mean any
means of delivery, whether in vivo or in vitro, including
simple contact.

De?nitions
As used herein, the term “antibody” means an immunoglo
bulin molecule, or a fragment of an immunoglobulin mol

ecule, having the ability to speci?cally bind to a particular
antigen. Antibodies are well known to those of ordinary skill
in the science of immunology. As used herein, the term “anti
body” means not only intact antibody molecules but also

fragments of antibody molecules retaining antigen-binding

20

ability. Such fragments are also well known in the art and are

regularly employed both in vitro and in vivo. In particular, as
used herein, the term “antibody” means not only intact immu
noglobulin molecules but also the well-known active frag

ments F(ab')2, Fab, Fv, Fd, VH and VL.

25

As used herein, the term “mimic” means the three-dimen
sional placement of atoms of the mimetic such that similar
ionic forces, covalent forces, van der Waal’s or other forces,
30

and similar charge complementarity, or electrostatic comple
mentarity, exist between the atoms of the mimetic and the
atoms of the binding site of the compound such as a peptide or
an antibody such that the mimetic has a similar binding a?in
ity for CD123 as the parent compound and/or such that the

and “IL3RO.” shall be used interchangeably to mean an anti

genic determinant that is detectable in leukemia precursor

of the antibody hypervariable loops or complementarity

determining regions (CDR’ s).

As used herein, the terms “bind” or “bind(s)” shall mean
any interaction, whether via direct or indirect means, which

affects the speci?ed receptor or receptor subunit.
As used herein, the terms “binds selectively to” shall mean
that the compound, composition, formulation, etc. does not
signi?cantly bind IL3R beta chain, but does bind IL3R alpha
chain.
As used herein, the terms “CD123”, “IL3R subunit alpha”

As used herein, the term “mimetic” means a compound or
molecule which mimics the three-dimensional structures of a
site on CD123 to which a compound may bind, or the com
pound may be a molecule that mimics a molecule that binds to
CD123. In the case of an anti-CD123 antibody binding site, or
paratope, or active site, “mimetic” means a compound that
mimics the three-dimensional structure of any combination

35

mimetic has a similar effect on the function of CD123 in vitro

cells as described herein, but not detectable on normal cells as

or in vivo.

described herein.
As used herein, the term “compoun

In the case of anti-CD123 antibodies, within the antigen
binding portion of an antibody, as is well-known in the art,

a,

shall mean any

purity of active ingredient, including formulations, composi
tions, naturally-occurring plants or animals, etc. The com
pound may include molecules that are naturally occurring,

there are complementarity determining regions (CDRs),
40

such as proteins, nucleic acids, single stranded nucleic acids,

lipids, carbohydrates, and antibodies. However, synthetic
versions of these naturally occurring molecules may be made,
so long as they bind CD123. The compounds may comprise

45

work regions (FRl through FR4) separated respectively by
three complementarity determining regions (CDR1 through
CDR3). The CDRs, and in particular the CDR3 regions, and

more than one component. For example, a compound may be
a monoclonal antibody attached to a toxin. Or, it may be a
lipid attached to a label. The compounds may further com

more particularly the heavy chain CDR3, are largely respon

sible for antibody speci?city.

prise mimetics, and aptamers, but which all retain their speci
?city to CD123.
As used herein, the term “impair” shall mean any decrease

which directly interact with the epitope of the antigen, and
framework regions (FRs), which maintain the tertiary struc
ture of the paratope. In both the heavy chain Fd fragment and
the light chain of IgG immunoglobulins, there are four frame

50

As used herein, the term “normal” means any non-patho
genic or non-pathology-related cells or conditions.

in functionality or activity (including growth or proliferative

As used herein, the terms “primitive” and “progenitor”
shall be interchangeable. As used herein, with respect to

activity).

polypeptides and antibodies, the term “substantially pure”

As used herein, the term “hematologic cancer” refers to a
cancer of the blood, and includes leukemia and malignant

55

lymphoproliferative disorders, among others. “Leukemia”
refers to a cancer of the blood, in which too many white blood
cells that are ineffective in ?ghting infection are made, thus

crowding out the other parts that make up the blood, such as
platelets and red blood cells. It is understood that cases of

60

acute leukemias are blocked at an immature stage. However,

they continue to multiply. Consequently, there is a large accu
mulation of non-functional immature cells and the concomi

slowly, with cancer cells developing to full maturity. Further
more, the white blood cells may be myelogenous or lym

generating antibodies, sequencing, or producing pharmaceu
tical preparations. By techniques well known in the art, sub
stantially pure polypeptides may be produced in light of the

leukemia are classi?ed as acute or chronic. Cancer cells in

tant loss of functional cells. Chronic leukemias progress more

means that the polypeptides are substantially free of other
substances with which they may be found in nature or in vivo
systems to an extent practical and appropriate for their
intended use. In particular, the polypeptides are suf?ciently
pure and are suf?ciently free from other biological constitu
ents of their host cells so as to be useful in, for example,

nucleic acid and amino acid sequences disclosed herein.
65

Because a substantially puri?ed polypeptide of the invention
may be admixed with a pharmaceutically acceptable carrier
in a pharmaceutical preparation, the polypeptide may com

prise only a small percentage by weight of the preparation.
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The polypeptide is nonetheless substantially pure in that it has
been substantially separated from the substances with which
it may be associated in living systems.
As used herein with respect to compounds or mimetics, the

screened for high af?nity binding to CD123 and detect and/or
impair the CD123 bearing cell in vitro or in vivo, as described
in more detail below.

Diagnostic and Pharmaceutical Preparations
The invention also relates to a method for preparing diag

term “substantially pure” means that the compounds are sub

nostic or pharmaceutical compositions comprising the
CD123 binding compound and its mimetics. The pharmaceu

stantially free of other substances with which they may be
found, in nature, in in vivo systems; or as a result of chemical
or other synthesis, to an extent practical and appropriate for
their intended use. In particular, the compounds are suf?

tical preparation includes a pharmaceutically acceptable car

ciently pure and are suf?ciently free from other biological

rier. Such carriers, as used herein, mean non-toxic materials
that do not interfere with the effectiveness of the biological

constituents of their hosts cells, or chemical or physical con

activity of the active ingredients. The term “physiologically

stituents of their synthesis so as to be useful in, producing

acceptable” refers to a non-toxic material that is compatible
with a biological system such as a cell, cell culture, tissue, or
organism. The characteristics of the carrier will depend on the

pharmaceutical preparations. By techniques well known in
the art (US. Pat. No. 5,648,379; Colman, P. G. Protein Sci
ence 3: 1687-1696, 1994; Malby, et al., Structure 2: 733-746,

route of administration. Physiologically and pharmaceuti

cally acceptable carriers include diluents, ?llers, salts, buff

1994; McCoy et al., 1 Molecular Biol. 268: 570-584, 1997),
substantially pure compounds or mimetics, may be designed.
Because a substantially puri?ed compound of the invention
may be admixed with a pharmaceutically acceptable carrier
in a pharmaceutical preparation, the compound may com

20

prise only a small percentage by weight of the preparation.
The compound is nonetheless substantially pure in that it has
been substantially separated from the substances with which
it may be associated in living, chemical or other systems.
Mimetics That Bind to CD123

25

ers, stabilizers, solubilizers, and other materials that are well
known in the art.
The anti-CD123 antibodies and mimetics may be labeled
by a variety of means for use in diagnostic and/or pharma
ceutical applications. There are many different labels and
methods of labeling known to those of ordinary skill in the art.
Examples of the types of labels which can be used in the

present invention include enzymes, radioisotopes, ?uores
cent compounds, colloidal metals, chemiluminescent com

Compounds that target CD123 can be found. Phage display

pounds, and bioluminescent compounds. Those of ordinary

libraries can be used to determine the DNA encoding the

skill in the art will know of other suitable labels for binding to
the CD123 binding compound, such as monoclonal antibod
ies, or mimetics thereof, or will be able to ascertain such,

polypeptide that binds to CD123. The principles of this
approach are disclosed in US. Pat. No. 5,837,500, which is
incorporated by reference herein in its entirety. Other non
peptide molecules that may bind to CD123 include nucleic
acids, and liposomes. Carbohydrates may also be used to
target CD123. It is possible that the compound may not be a

naturally occurring biological molecule. Such chemicals may

30

using routine experimentation. Furthermore, the binding of

35

be made by combinatorial libraries which are well known in

these labels to the CD123 speci?c compounds or their mimet
ics canbe done using standard techniques common to those of
ordinary skill in the art.
In the case of antibodies, another labeling technique which

the art, with the assay goal being the binding of the chemical

may result in greater sensitivity consists of coupling the anti

compound to CD123. Liposomes may ensconce certain tox
ins or other cell-impairing substances or cell-imaging com

bodies or mimetics to low molecular weight haptens. These
haptens can then be speci?cally altered by means of a second

pounds may be used to target CD123. Numerous variations

40

reaction. For example, it is common to use haptens such as

and combinations of compounds as targeting agents are con

biotin, which reacts with avidin, or dinitrophenol, pyridoxal,

templated by the method of the invention, so long as CD123
is targeted, with the knowledge that leukemia detection and
leukemia treatment is kept in mind.
Mimetics of Anti-CD123 Antibodies
It is also possible to use the anti-idiotype technology to

or ?uorescein, which can react with speci?c anti-hapten anti
bodies.

Diagnostic and Treatment Kits
45

isolate or screen for compounds or mimetics which mimic an

epitope. Thus, an anti-idiotypic monoclonal antibody which
is the image of the epitope bound by the ?rst monoclonal
antibody, since it effectively acts as an antigen, may be used

in close con?nement one or more container means such as
50

vials, tubes, and the like, each of the container means com
prising one of the separate elements to be used in the method.
For example, one of the container means may comprise a
compound that binds to CD123, such as a monoclonal anti
body, or a mimetic thereof, which is, or can be, detectably
labeled with a label that is suitable for diagnostic purposes or

to isolate mimetics from a combinatorial chemical, or other

libraries, of chemical or other compounds, such as peptide

phage display libraries (Scott and Smith, Science 249: 386
390, 1990; Scott and Craig, Curr. Opin. Biotechnol. 5: 40-48,
1992; Bonnycastle et al., J. Mol. Biol. 258: 747-762, 1996).
Hence, peptides or constrained peptides mimicking proteins
or other compounds, including those with nucleic acid, lipid,

The materials for use in the assay of the invention are

ideally suited for the preparation of a kit. Such a kit may
comprise a carrier means being compartmentalized to receive

55

if treatment is desired, a cytotoxic or impairing agent. In the
case of a diagnostic kit, the kit may also have containers
containing buffer(s) and/or a container comprising a reporter

carbohydrate or other moieties, may be cloned (Harris et al.,
Proc. Natl. Acad. Sci. (USA) 94: 2454-2459, 1997).

means, such as a biotin-binding protein, such as avidin or
streptavidin, bound to a reporter molecule, such as an enzy
Purely synthetic molecules, which may not occur in nature 60 matic or ?uorescent label. In addition to the chemical mate
rial, of course a means of instructions for using the kit is
and are therefore more resistant to catabolism, excretion or

degradation, may be designed by the three-dimensional

included, preferably for either diagnosing leukemia, or treat

placement of atoms, such that similar ionic forces, covalent

ing leukemia. The instruction means may be written on the
vial, tube and the like, or written on a separate paper, or on the
outside or inside of the container. The instructions may also

forces, van der Waal’s or other forces, and similar charge
complementarity, or electrostatic complementarity, exist
between the atoms of the mimetic and the atoms of the anti
genic binding site or epitope. These mimetics may then be

65

be in the form of a multi-media format, such as CD, computer
disk, video and so on.
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Preparation of lmmunotoxins
While the preparation of immunotoxins is, in general, well

nevertheless realized. Other useful cross-linkers, not consid
ered to contain or generate a protected disul?de, include

known in the art (see, e.g., US. Pat. No. 4,340,535, and EP

SATA, SPDP and 2-iminothiolane. The use of such cross
linkers is well understood in the art.

44167, both incorporated herein by reference), the inventors

Once conjugated, it will be important to purify the conju

are aware that certain advantages may be achieved through

the application of certain preferred technology, both in the
preparation of the immunotoxins and in their puri?cation for
subsequent clinical administration. For example, while lgG
based immunotoxins will typically exhibit better binding

gate so as to remove contaminants such as unconjugated A

chain or binding agent. It is important to remove unconju

gatedA chain because of the possibility of increased toxicity.
Moreover, it is important to remove unconjugated binding
agent to avoid the possibility of competition for the antigen
between conjugated and unconjugated species. In any event,

capability and slower blood clearance than their Fab' coun

terparts, Fab' fragment-based immunotoxins will generally
exhibit better tissue penetrating capability as compared to
lgG based immunotoxins.

a number of puri?cation techniques are disclosed in the

Examples below which have been found to provide conju
gates to a suf?cient degree of purity to render them clinically
useful. In general, the most preferred technique will incorpo

Additionally, while numerous types of disul?de-bond con
taining linkers are known which can successfully be

employed to conjugate the toxin moiety with the binding
agent, certain linkers will generally be preferred over other
linkers, based on differing pharmacologic characteristics and
capabilities. For example, linkers that contain a disul?de
bond that is sterically “hindered” are to be preferred, due to

20

exchange withA chain binding to provide good separation of

their greater stability in vivo, thus preventing release of the
toxin moiety prior to binding at the site of action.
Cross-linking reagents are used to form molecular bridges
that tie together functional groups of two different proteins
(e.g., a toxin and a binding agent). To link two different

conjugated from unconjugated binding.
The Blue-Sepharose allows the elimination of the free (non

conjugated) binding agent (e.g., the antibody or fragment)
25

proteins in a step-wise manner, hetero bifunctional cross
linkers can be used which eliminate the unwanted homopoly
mer formation. An exemplary hetero bifunctional cross
linker contains two reactive groups: one reacting with

primary amine group (e.g., N-hydroxy succinimide) and the

After a suf?ciently puri?ed conjugate has been prepared,
30

pharmaceutical composition.
Suitable pharmaceutical compositions in accordance with
35

sulfhydryl group) of the other protein (e. g., dgA).
40

conjugate components while some particular components in
the bridge (e.g., benzene group) may lend extra stability to the
reactive group or an increased resistance of the chemical link
45

is a bifunctional cross-linker containing a disul?de bond that

is “sterically hindered” by an adjacent benzene ring and
methyl groups. It is believed that stearic hindrance of the
50

present in tissues and blood, and thereby help in preventing
decoupling of the conjugate prior to its delivery to the site of
action by the binding agent. The SMPT cross-linking reagent,
as with many other known cross-linking reagents, lends the
ability to cross-link functional groups such as the SH of

maceutically acceptable by insuring their sterility, non-im
munogenicity and non-pyrogenicity. Such techniques are
generally well known in the art as exempli?ed by Reming
ton’s Pharmaceutical Sciences, 16th Ed. Mack Publishing
Company, 1980, incorporated herein by reference. It should
be appreciated that endotoxin contamination should be kept
minimally at a safe level, for example, less than 0.5 ng/mg

protein. Moreover, for human administration, preparations
should meet sterility, pyrogenicity, general safety and purity
55

standards as required by FDA Of?ce of Biological Standards.
A preferred parenteral formulation of the immunotoxins in
accordance with the present invention is 0.25 to 2.5 mg con

cysteine or primary amines (e.g., the epsilon amino group of
lysine). Another possible type of cross-linker includes the
hetero-bifunctional photoreactive phenylazides containing a
cleavable disul?de bond such as sulfosuccinimidyl-2-(p

2.5 mg/ml with respect to the conjugate. Such formulations
will typically include buffers such as phosphate buffered
saline (PBS), or additional additives such as pharmaceutical
excipients, stabilizing agents such as BSA or HSA, or salts
such as sodium chloride. For parenteral administration it is

generally desirable to further render such compositions phar

to the action of various aspects (e.g., disul?de bond resistant

disul?de bond serves a function of protecting the bond from
attack by thiolate anions such as glutathione which can be

the invention will generally comprise from about 10 to about
100 mg of the desired conjugate admixed with an acceptable
pharmaceutical diluent or excipient, such as a sterile aqueous
solution, to give a ?nal concentration of about 0.25 to about

The spacer arm between these two reactive, groups of any

to reducing agents).
The most preferred cross-linking reagent is SMPT, which

one will desire to prepare it into a pharmaceutical composi

tion that may be administered parenterally. This is done by
using for the last puri?cation step a medium with a suitable

other reacting with a thiol group (e. g., pyridyl disul?de, male

cross-linkers may have various lengths and chemical compo
sitions. A longer spacer arm allows a better ?exibility of the

from the conjugate preparation. To eliminate the free (uncon
jugated) toxin (e.g., dgA) a molecular exclusion chromatog
raphy step is preferred using either conventional gel ?ltration

procedure or high performance liquid chromatography.

imides, halogens, etc.). Through the primary amine reactive
group, the cross-linker may react with the lysine residue(s) of
one protein (e.g., the selected antibody or fragment) and
through the thiol reactive group, the cross-linker, already tied
up to the ?rst protein, reacts with the cysteine residue (free

rate the use of Blue-Sepharose with a gel ?ltration or gel
permeation step. Blue-Sepharose is a column matrix com
posed of Cibacron Blue. 3GA and agarose, which has been
found to be useful in the puri?cation of immunoconjugates.
The use of Blue-Sepharose combines the properties of ion

jugate/ml in 0.15M NaCl aqueous solution at pH 7.5 to 9.0.
The preparations may be stored frozen at —100 C. to —700 C.
for at least 1 year.
60

azido salicylamido)ethyl-1,3'-dithiopropionate. The N-hy
droxy-succinimidyl group reacts with primary amino groups

It is contemplated that most therapeutic applications of the
present invention will involve the targeting of a toxin moiety
(cytotoxic agent) to the CD123 leukemia marker. This is due

and the phenylazide (upon photolysis) reacts non-selectively

to the much greater ability of most toxins to deliver a cell

with any amino acid residue.

killing effect as compared to other potential agents.

Although the “hindered” cross-linkers will generally be
preferred in the practice of the invention, non-hindered link
ers can be employed and advantages in accordance herewith

65

However, there may be circumstances such as when the
target antigen does not internalize by a route consistent with
ef?cient intoxication by immunotoxins, where one will desire

US 8,852,551 B2
11

12

to target chemotherapeutic agents such as cytokines, antime

antibodies in these immunoassays can be detectably labeled
in various ways. Examples of types of immunoassays which

tabolites, alkylating agents, hormones, and the like. The
advantages of these agents over their non-antibody conju
gated counterparts is the added selectivity afforded by the
antibody. One might mention by way of example agents such
as steroids, cytosine arabinoside, methotrexate, aminopterin,

can utilize the monoclonal antibodies and their mimetics are

competitive and non-competitive immunoassays in either a
direct or indirect format. Examples of such immunoassays are

the radioimmunoassay (RIA) and the sandwich (immuno
metric) assay. Detection of antigens using the monoclonal

anthracyclines, mitomycin C, vinca alkaloids, demecolcine,
etopside, mithramycin, and the like. This list is, of course,

antibodies and their mimetics can be done utiliZing immu

merely exemplary in that the technology for attaching phar

noassays which are run in either the forward, reverse, or

maceutical agents to antibodies for speci?c delivery to tissues
is well established.
One preferred cytotoxic moiety for use in the present

on physiological samples. Those of skill in the art will know,
or can readily discern, other immunoassay formats without

invention is a radioisotope, which can be coupled to or con

undue experimentation.

jugated with, for example, an anti-CD 123 antibody. Preferred
radioisotopes include (x-emitters such as, for example,
leAstatine, 212Bismuth and 213Bismuth, as well as [3-emit
ters such as, for example, 13 lIodine, 90Yttrium, 177Lutetium,
153 Samarium and 109Palladium. Particularly preferred radio
isotopes are 211Astatine and 131Iodine.
It is proposed that particular bene?ts may also be achieved
through the application of the invention to cell imaging.
Imaging of leukemia cells is believed to provide a major

The compounds that bind CD123 and mimetics can be
bound to many different carriers and used to detect the pres

simultaneous modes, including immunohistochemical assays

ence of CD123 bearing leukemia cells, including progenitor
cells. Examples of well-known carriers include glass, poly

styrene, polypropylene, polyethylene, dextran, nylon, amy
lase, natural and modi?ed cellulose, polyacrylamide, agarose
20

advantage when compared to available imaging techniques,

compounds, or will be able to ascertain such, using routine

experimentation.

in that the cells are readily accessible.

Moreover, the technology for attaching paramagnetic,

and magnetite. The nature of the carrier can be either soluble
or insoluble for purposes of the invention. Those skilled in the
art will know of other suitable carriers for binding various

25

radioactive and even ?uorogenic ions to antibodies is well
established. Many of these methods involve the use of a metal

chelate complex employing, for example, an organic chelat

For purposes of the invention, CD123 may be detected by
the compounds and their mimetics when present in biological
?uids and tissues. Any sample containing a detectable amount

tion the selected ion is thus targeted to the cancerous area by

of CD123 ectopeptide can be used. A sample can be a liquid
such as urine, saliva, cerebrospinal ?uid, blood, serum or the
like; a solid or semi-solid such as tissues, feces, or the like; or,
alternatively, a solid tissue such as those commonly used in

the antibody, allowing imaging to proceed by means of the

histological diagnosis.

attached ion.
In a preferred embodiment, in the method of the invention,
the antibodies may also be fused to a protein effector mol
ecule by recombinant means such as through the use of
recombinant DNA techniques to produce a nucleic acid
which encodes both the antibody and the effector molecule
and expressing the DNA sequence in a host cell such as E.

In Vivo Detection of CD123

ing agent such a DTPA attached to the antibody (see, e.g.,
US. Pat. No. 4,472,509). In the context of the present inven

coli. The DNA encoding the chimeric protein may be cloned
in cDNA or in genomic form by any cloning procedure known
to those skilled in the art. See for example Sambrook et al.,

30

In using the CD123 binding compounds and mimetics for
35

40

Molecular Cloning: A Laboratory Manual, Cold Spring Har
bor Laboratory, (1989), which is herein incorporated by ref
erence.

45

detectable compared to the background. Further, it is desir
able that the detectably labeled compound or mimetic be
rapidly cleared from the circulatory system in order to give
the best target-to-background signal ratio.
As a rule, the dosage of detectably labeled compound or

50

mimetic for in vivo diagnosis will vary depending on such

Fusion or conjugation of antibodies to various labels pro
duces a highly speci?c detectable marker that may be used to
detect the presence or absence of cells or tissues bearing the

particular molecule to which the antibody is detected. Alter
natively, the antibodies may be chemically conjugated or
fused to an effector molecule that is another speci?c binding
moiety, e.g. a ligand such as those described above. In this
form the composition will act as a highly speci?c bifunctional
linker. This linker may act to bind and enhance the interaction
between cells or cellular components to which the fusion

the in vivo detection of CD123, the detectably labeled com
pound or its mimetic is given in a dose which is diagnostically
effective. The term “diagnostically effective” means that the
amount of detectably labeled compound, such as monoclonal
antibody or mimetic is administered in suf?cient quantity to
enable detection of the leukemia cells for which the com
pounds or mimetics are speci?c.
The concentration of detectably labeled compound or
mimetic which is administered should be suf?cient such that
the binding to CD123 or CD123-bearing leukemia cells, is

factors as age, sex, and extent of disease of the individual. The

dosage of the compound can vary from about 0.01 mg/kg to
about 500 mg/kg, preferably about 0.1 mg/kg to about 200
55

protein binds. Thus, for example, where the fusion protein is

mg/kg, most preferably about 0.1 mg/kg to about 10 mg/kg.
Such dosages may vary, for example, depending on whether
multiple injections are given, on the tissue being assayed, and

a growth factor joined to an antibody or antibody fragment
(e.g. an Fv fragment of an antibody), the antibody may spe

other factors known to those of skill in the art.

ci?cally bind antigen positive cancer cells while the growth

ment available is a major factor in selecting an appropriate
radioisotope. The radioisotope chosen must have a type of

factor binds receptors on the surface of immune cells. The
fusion protein may thus act to enhance and direct an immune
response toward target cancer cells.

For in vivo diagnostic imaging, the type of detection instru
60

decay which is detectable for the given type of instrument.
Still another important factor in selecting a radioisotope for in
vivo diagnosis is that the half-life of the radioisotope be long

In Vitro Detection and Diagnostics
The method of using the compounds that bind to CD123
and their mimetics are suited for in vitro use, for example, in

immunoassays in which they canbe utilized in liquid phase or
bound to a solid phase carrier. In addition, the monoclonal

enough such that it is still detectable at the time of maximum
65

uptake by the target, but short enough such that deleterious
radiation with respect to the host is acceptable. Ideally, a
radioisotope used for in vivo imaging will lack a particle
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emission but produce a large number of photons in the 140
250 keV range, which may be readily detected by conven

jugated to antibodies in a manner that will allow their target

ing, internalization, release or presentation to blood compo
nents at the site of the targeted leukemia cells as required

tional gamma cameras.

using known conjugation technology.

For in vivo diagnosis, radioisotopes may be bound to the

compound either directly or indirectly by using an interme

In certain preferred embodiments, cytotoxic agents for
therapeutic application will include generally a plant-, fun

diate functional group. Intermediate functional groups which
often are used to bind radioisotopes which exist as metallic
ions are the bifunctional chelating agents such as diethylen

gus- or bacteria-derived toxin, such as an A chain toxins, a

ribosome inactivating protein, (x-sarcin, aspergillin, restiric

etriaminepentacetic acid (DTPA) and ethylenediaminetetra

tocin, a ribonuclease, diphtheria toxin or pseudomonas exo
toxin, to mention just a few examples. The use of toxin
antibody constructs is well known in the art of immunotoxins,
as is their attachment to antibodies. Of these, a particularly
preferred toxin for attachment to antibodies will be a degly

acetic acid (EDTA) and similar molecules. Typical examples
of metallic ions which can be bound to the monoclonal anti

bodies and mimetics of the invention are 111In, 97Ru, 67Ga,

68Ga, 72As, 89Zr, 99"'Tc, 123I and 201T1.
In the diagnosis method of the invention, the compounds

cosylated ricin A chain. Deglycosylated ricin A chain is pre
ferred because of its extreme potency, longer half-life, and

and mimetics can also be labeled with a paramagnetic isotope
for purposes of in vivo diagnosis, as in magnetic resonance

because it is economically feasible to manufacture a clinical

grade and scale.
In other preferred embodiments, the cytotoxic agent may

imaging (MRI) or electron spin resonance (ESR). In general,
any conventional method for visualizing diagnostic imaging
can be utilized. Usually gamma and positron emitting radio
isotopes are used for camera imaging and paramagnetic iso
topes for MRI. Elements which are particularly useful in such

be a radioisotope. Preferred radioisotopes include (x-emitters
20

such as, for example, 211Astatine, 212Bismuth and 213Bis

techniques include 157Gd, 55Mn, 162Dy, 52Cr and 56Fe.

muth, as well as [3-emitters such as, for example, 13lIodine,
90Yttrium, 177Lutetium, 15 3 Samarium and 109Palladium.

In the cell monitoring method of the invention, the com
pounds and mimetics can be used in vitro and in vivo to
monitor the course of leukemia disease therapy. Thus, for

compound is a dosage large enough to produce the desired

As used herein, a “therapeutically effective amount” of a
25

example, by measuring the increase or decrease in the bio
logical molecules associated with such a diseases or changes
in the concentration of CD123 ectopeptide or CD123 bearing
leukemia cells present in the body or in various body ?uids, it
would be possible to determine whether a particular thera

effect in which the symptoms of leukemia or the likelihood of
onset of leukemia is decreased. A therapeutically effective
amount is not, however, a dosage so large as to cause adverse

side effects, such as hyperviscosity syndromes, pulmonary
edema, congestive heart failure, and the like. Generally, a
30

therapeutically effective amount may vary with the subject’ s

peutic regimen aimed at ameliorating the above leukemia

age, condition, and sex, as well as the extent of the disease in

disease is effective.

the subject and can be determined by one of skill in the art.

Prophylaxis and Therapy of Leukemia

The dosage may be adjusted by the individual physician or
veterinarian in the event of any complication. A therapeuti
cally effective amount may vary from about 0.01 mg/kg to
about 500 mg/kg, preferably from about 0.1 mg/kg to about
200 mg/kg, most preferably from about 0.2 mg/kg to about 20

The CD123 speci?c compounds can also be used therapeu
tically for treatment of leukemia in both humans and other
animals. The term, “therapeutically” or “therapy” as used
herein in conjunction with the method of the invention is
directed to using CD123 binding compounds, such as anti
CD123 monoclonal antibodies and their mimetics, which
denotes both prophylactic as well as therapeutic administra

35

mg/kg, in one or more dose administrations daily, for one or

several days.
40

tion and both passive immunization with substantially puri

In the method of the invention, the compounds and their
mimetics can be administered by injection or by gradual

?ed polypeptide products, and mimetics, as well as gene

infusion over time. The administration of the compounds and

therapy by transfer of polynucleotide sequences encoding the

their mimetics may be, for example, intravenous, intraperito
neal, intramuscular, intracavity, subcutaneous, or transder

product or part thereof. Thus, the compounds and mimetics
can be administered to high-risk subjects in order to lessen the
likelihood and/or severity of leukemia relapse, or adminis

45

Preparations for parenteral administration include sterile

tered to subjects already evidencing active leukemia disease.
For certain applications, it is envisioned that pharmaco

aqueous or non-aqueous solutions. suspensions, and emul

logic agents will serve as useful agents for attachment to the

compounds, particularly cytotoxic or otherwise anticellular

50

agents having the ability to kill or suppress the growth or cell
division of leukemia cells. In general, the invention contem
plates the use of any pharmacologic agent that can be conju
gated to a CD123 binding compound and delivered in active

form to the targeted cell. Exemplary anticellular agents

suspensions, including saline and buffered media. Parenteral
vehicles include sodium chloride solution, Ringer’ s dextrose,
dextrose and sodium chloride, lactated Ringer’ s or ?xed oils.
55

tors propose that agents such as a hormone such as a steroid;

cheamicin, CC-1065 and derivatives thereof, or an alkylating
agent such as chlorambucil or melphalan, will be particularly
preferred. Other embodiments may include agents such as a
coagulant, a cytokine, growth factor, bacterial endotoxin or
the lipid A moiety of bacterial endotoxin. In any event, it is
proposed that agents such as these may be successfully con

sions. Examples of non-aqueous solvents are propylene gly
col, polyethylene glycol, vegetable oils such as olive oil, and
injectable organic esters such as ethyl oleate. Aqueous carri
ers include water, alcoholic/aqueous solutions, emulsions or

include chemotherapeutic agents, radioisotopes as well as
cytotoxins. In the case of chemotherapeutic agents, the inven
an antimetabolite such as cytosine arabinoside, ?uorouracil,
methotrexate or aminopterin; an anthracycline; mitomycin C;
a vinca alkaloid; demecolcine; etoposide; mithramycin; cali

mal.

60

Intravenous vehicles include ?uid and nutrient replenishers,
electrolyte replenishers (such as those based on Ringer’s
dextrose), and the like. Preservatives and other additives may
also be present such as, for example, antimicrobials, anti
oxidants, chelating agents, and inert gases and the like.
Depending on the speci?c clinical status of the disease,
administration can be made via any accepted systemic deliv
ery system, for example, via oral route or parenteral route
such as intravenous, intramuscular, subcutaneous or percuta
neous route, or vaginal, ocular or nasal route, in solid, semi

65

solid or liquid dosage forms, such as for example, tablets,

suppositories, pills, capsules, powders, solutions, suspen
sions, cream, gel, implant, patch, pessary, aerosols, col
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lyrium, emulsions or the like, preferably in unit dosage forms
suitable for easy administration of ?xed dosages. The phar

Blood 1996, 88: 1944-50). Thus, a better understanding of
LSC biology and the characterization of unique LSC antigens

maceutical compositions will include a conventional carrier
or vehicle and a CD123 binding compound and, in addition,

are essential to the development of better treatments forAML.

may include other medicinal agents, pharmaceutical agents,

diversity with respect to developmental characteristics, phe

While the various AML subtypes display considerable
notype, cytokine responsiveness, etc., there appears to be a

carriers, adjuvants, and so on.

If desired, the pharmaceutical composition to be adminis

marked degree of functional conservation at the level of more

primitive leukemic cells. This feature has been demonstrated
by the work of Bonnet et. al., in which a CD34+/CD38—
subpopulation was shown to be suf?cient to establish leuke
mia in NOD/SCID mice (Bonnet D, et al., Human acute

tered may also contain minor amounts of non-toxic auxiliary
substances such as wetting or emulsifying agents, pH buffer

ing agents and the like, such as for example, sodium acetate,
sorbitan monolaurate, triethanolamine oleate, and so on.

The compounds of this invention are generally adminis
tered as a pharmaceutical composition which comprises a
pharmaceutical vehicle in combination with a CD 1 23 binding
compound. The amount of the drug in a formulation can vary

myeloid leukemia is organized as a hierarchy that originates
from a primitive hematopoietic cell. Nat. Med. 1997, 3: 730
737). Similar studies by others have corroborated the exist

within the full range employed by those skilled in the art, e.g.,
from about 0.01 weight percent (wt %) to about 99.99 wt % of

con?rmed their relatively homogeneous phenotype and func
tional capacity (Blair A, Hogge et al., Most acute myeloid
leukemia progenitor cells with long-term proliferative ability

ence of leukemic stem cells for both AML and CML and

the drug based on the total formulation and about 0.01 wt %
to 99.99 wt % excipient.

The preferred mode of administration, for the conditions
mentioned above, is oral administration using a convenient
daily dosage regimen which can be adjusted according to the
degree of the complaint. For said oral administration, a phar

20

maceutically acceptable, non-toxic composition is formed by
the incorporation of the selected CD123 binding compound
in any of the currently used excipients, such as, for example,

25

report, we have identi?ed an additional commonality among

pharmaceutical grades of mannitol, lactose, starch, magne
sium stearate, sodium saccharine, talc, cellulose, glucose,
gelatin, sucrose, magnesium carbonate, and the like. Such
compositions take the form of solutions, suspensions, tablets,
pills, capsules, powders, sustained release formulations and
the like. Such compositions may contain between about 0.01
wt % and 99.99 wt % of the active compound according to this
invention.
Preferably the compositions will have the form of a sugar

CD34+/CD38— AML stem cells, expression of CD123,
30

Our experiments indicate that the transcription factor
35

40

done, acacia gum, gelatin, cellulose and derivatives thereof,

45

sion of CD123 (data not shown). Thus, aberrant expression of
interferon regulatory molecules might play a role in control
ling CD123 expression in AML cells.

Expression of the CD123 antigen formally demonstrates

or treating leukemia in the individual. And, by “pharmaceu
tical composition”, it excludes those compositions that are

that LSC’s are biologically distinct from their normal stem
cell counterparts. Because CD123 is not readily found on

used to administer to individuals as test compounds for a
purpose other than as a diagnostic or treatment agent for

normal hematopoietic stem cells, it provides a unique marker
50

that can be used to identify malignant tissue. This feature may
be useful for research purposes, as well as in minimal residual

disease (MRD) studies. Further, the CD123 epitope repre

importance of stem cells in both the genesis and perpetuation
ofAML. Phenotypically, cells described as CD34+/CD38— or
CD34+/HLA-DR— appear to play a central role in the devel

synergizes with IL-3 in stimulating major histocompatibility
complex class II expression and cytokine production. Blood
1995, 86: 176-82). Similarly, our own studies have shown that
treatment of primary AML cells with IFN-y increases expres

It is understood that by “pharmaceutical composition”, it is

leukemia.
The invention is described in further detail hereinbelow.
Several recent studies have suggested the presence and

Korpelainen et. al. have shown that treatment of endothelial

cells with IFN-y results in up-regulation of CD123 (Korpel
ainen E I, et al., Interferon-gamma upregulates interleukin-3
(IL-3) receptor expression in human endothelial cells and

and the like.

meant that the CD123 binding compound is formulated into a
substance that is to be administered purposefully diagnosing

which facilitates their discrimination from normal hemato
poietic stem cells. While the CD123 antigen was readily
detected at high levels on AML cells, the IL-3 receptor [3
chain, CD131, was not detected.

IRF-l (Interferon regulatory factor-1) is over-expressed (in 6
of 6 primary AML specimens examined). Previous studies by

coated pill or tablet and thus they will contain, along with the
active ingredient, a diluent such as lactose, sucrose, dicalcium
phosphate, and the like; a disintegrant such as starch or
derivatives thereof; a lubricant such as magnesium stearate
and the like; and a binder such as starch, polyvinylpyrroli

in vitro and in vivo have the phenotype CD34(+)/CD71(—)/
HLA-DR—. Blood 1998, 92: 4325-35; Holyoake T, et al.,
Isolation of a highly quiescent subpopulation of primitive
leukemic cells in chronic myeloid leukemia. Blood 1999, 94:
2056-64). However, to date, no study has identi?ed an anti
genic feature of myeloid LSC’s that may allow their identi
?cation or preferential targeting for ablative therapy. In this

sents a target to which therapeutic strategies may be directed.
Previous clinical trials have used monoclonal antibodies
55

against both the CD33 and CD45 antigens as a means to

opment of leukemic populations (Bonnet D, et al., Human

deliver radioisotopes to AML cells in vivo (Appelbaum F R.,

acute myeloid leukemia is organized as a hierarchy that origi
nates from a primitive hematopoietic cell. Nat. Med. 1997, 3:
730-737; Blair A, et al., Most acute myeloid leukemia pro

Antibody-targeted therapy for myeloid leukemia. Semin

genitor cells with long-term proliferative ability in vitro and
in vivo have the phenotype CD34(+)/CD71(—)/HLA-DR—.
Blood 1998, 92: 4325-35). Furthermore, there is evidence

60

therapy of hematologic malignancies. Curr Opin Hematol

suggesting that such cells may be relatively resistant to che

motherapeutic drugs, and consequently contribute to the phe
nomenon of relapse (Terpstra W, et al., Fluorouracil selec
tively spares acute myeloid leukemia cells with long-term
growth abilities in immunode?cient mice and in culture.

Hematol 1999, 36: 2-8.). In addition, several other recent
studies have shown exciting results using monoclonal anti
bodies speci?c to antigens on malignant cells such as CD20,
CD52, and Her-2 (Maloney D G., Advances in immuno

65

1998; 5: 237-43; Sikic B I., New approaches in cancer treat
ment. Ann Oncol 1999, 10 Suppl 6: 149-53). Antibodies to
CD123 may be useful in a similar paradigm and will be

capable of delivering a cytotoxic hit that speci?cally targets
the leukemic stem cell population.

US 8,852,551 B2
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We have shown that CD123 represents a unique antigenic
marker for the identi?cation of primitive leukemic cells from

Example 3

a broad range of human specimens across a broad range of

Immunoblots

leukemic diseases. Our studies show that CD123 is generally
expressed at high levels and may be indicative of previously

5

uncharacterized aspects of leukemia biology.

Cell samples were lysed at a concentration of 2><107 cells/

ml in PBS containing: 1% NP-40, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 1 mM sodium vanadate

The present invention will be further illustrated in the fol

lowing, non-limiting Examples. The Examples are illustra

(Na3VO4), 30 pl aprotinin (Sigma), 1 mM phenylmethylsul
fonyl ?uoride (Sigma), 1 11ng pepstatin, and 1 11ng leu

tive only and do not limit the claimed invention regarding the
materials, conditions, process parameters and the like recited
herein.

peptin (Oncogene Research); incubated on ice for 30 minutes,

EXAMPLES

The resulting protein lysate was then aliquoted and stored at
—80° C. For immunoblot analysis, protein lysates were
thawed and mixed with sample buffer and reducing agent

Example 1

and heated at 70° C. for 10 minutes. Samples were then

Materials and Methods: Cell Processing

Bis-Tris or 7% Tris-Acetate gels) using the equivalent of

and centrifuged at 15,000><g for 10 minutes to remove debris.

(Novex, San Diego, Calif., per manufacturer’s instructions),

immediately analyzed by denaturing PAGE (Novex, 4-12%
4><105 cells per lane. Following electrophoresis, samples
20

Primary AML cells were obtained from the peripheral

lipore) and probed with the indicated antibodies. To detect

blood or bone marrow of patients. Normal bone marrow was

CD123 (IL-3R alpha chain), antibodies S-12 (Santa Cruz

obtained as waste material following pathological analysis,

Biotech) or 9F5 (Pharmingen) were used. For the analysis of

surgical marrow harvest, or from the National Disease

Research Interchange (NDRI). Marrow cells were depleted of

Mek and Akt, protein-speci?c and phosphoprotein-speci?c
25

erythrocytes by suspending in 150 mM NH4Cl+10 mM
NaHCO3 for 5 minutes, followed by two washes with phos

the phosphorylation status of Stat5. All primary antibodies

Ficoll-Paque (Pharmacia) density gradient separation to iso

were detected using alkaline phosphatase-conjugated sec
30

ondary antibodies (Santa Cruz Biotechnology) and the ECF
reagent (Pharmacia Biotech) per manufacturer’ s instructions.
Blots were visualized using a Molecular Dynamics STORM
860 system and ImagequantTM Software.

35

Example 4

ing leukocytes from marrow or blood were then used for

immunoaf?nity selection, and/ or ?ow cytometric analysis or
sorting. For CD34+ cell selection, the Miltenyi immunoa?in
ity device (varioMACS) was used according to the manufac
turer’s instructions. In some cases, leukocytes were cryopre

rabbit polyclonal antibodies from New England Biolabs were

used. Anti-Stat5 polyclonal (Transduction Labs) and anti
phospho-Stat5 (New England Biolabs) were used to analyze

phate buffered saline (PBS). Blood cells were subjected to
late the mononuclear white blood cell compartment. Result

were electro-transferred onto Immobilon-P membrane (Mil

served at a concentration of 5><107 cells/ml in freezing
medium consisting of Iscoves modi?ed Dulbecco medium

NOD/SCID Mouse Assays

(IMDM), 40% fetal bovine serum (FBS) and 10% dimethyl

sulfoxide (DMSO).

NOD/SCID mice (Jackson Laboratories, Bar Harbor, Me.)
Example 2

were exposed to 225 rads of y-irradiation from a 137Cs source.
Cells to be assayed were resuspended in 0.25 mls HBSS

Flow Cytometry

injected IV into the tail vein. For the analysis of some sorted
populations, 1><106 irradiated (2500 Rads) mouse bone mar

40

(Hanks balanced salt solution, Gibco) with 2% FBS and
45

Cytokine receptors were detected by labeling with the fol
lowing monoclonal antibodies: CD114-biotin, CD1 16-FITC,
CD123-PE, CD131-biotin (all from Pharmingen), CD117
PE (Coulter), and CD135-PE (Caltag). Biotinylated antibod
ies were visualized by subsequent labeling with streptavidin
PE (SA-PE, Becton Dickinson). Primitive AML

row cells were co-inj ected as carrier. After 6-8 weeks, animals
were sacri?ced and bone marrow was analyzed for the pres

ence of human cells using ?ow cytometry (see above).

Example 5
50

Results

subpopulations were identi?ed using CD34-FITC or CD34

Analysis of cytokine receptors demonstrates strong

PE in combination with CD38-APC (Becton Dickinson). Pri
mary AML cells were identi?ed in NOD/SCID mice using

CD45-PE (Pharmingen) speci?c to human cells. To analyze

55

expression of CD123 on primitive leukemic but not normal
cells. Multiparameter ?ow cytometry was used to analyze the

expression of cytokine receptors previously implicated in the
growth of malignant hematopoietic cells. While several

cells transplanted into NOD/SCID mice, bone marrow was
harvested at 6-8 weeks post-transplantation. Cells were

blocked with the anti-Fc receptor antibody 2.4G2 and 25%

receptors displayed interesting patterns of antibody labeling,

human serum, followed by double-labeling with human-spe

the most striking feature observed was a remarkably high and

ci?c CD34-FITC and CD45-PE antibodies. Control samples
consisted of marrow cells from non-transplanted mice. In
some cases, cells were also labeled with CD123-PE to ensure

well-conserved level of CD123 (IL-3R alpha chain) expres
sion amongst primary AML specimens. FIG. 1 shows repre
sentative examples of CD123 labeling in normal and leuke

sustained expression of the CD123 antigen. For each speci

mic tissue. In FIG. 1A total normal marrow, as well as more

men 50,000-100,000 events were analyzed. Using this
approach, human cells could reliably be detected to a fre
quency as low as 0.1%. Any analysis falling below 0.1%

positive cells was considered negative.

60

65

primitive subsets, are shown with respect to CD123 expres
sion. Total marrow generally has about 7% positive cells for

CD123, but only about 1% of the population expresses the
antigen at high levels (see inset FIG. 1A). The CD34+ popu

US 8,852,551 B2
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lation of normal marrow also has readily evident CD123

population of human cells (CD45+) is present in the marrow.
In addition, the population is divided between CD34+ and
CD34— subsets, similar to the proportions of CD34 labeling
seen in the original leukemic specimen. Panel B shows the

expression (12% in FIG. 1A, right histogram), as would be
expected for a population known to contain hematopoietic
progenitors. The labeling pro?le shown is in good agreement
with previous studies by Sato et. al. that have also examined
IL-3RO. levels on human CD34+ cells (Sato N, et al., Expres
sion and factor-dependent modulation of the interleukin-3
receptor subunits on human hematopoietic cells. Blood 1993,
82: 752-61.). However, the more primitive CD34+/CD38—
compartment shows no signi?cant expression of CD123

5

same marrow sample gated only on the CD45+ cells. The data
indicate that all of the cells that have proliferated in vivo are
CD123 positive. Table 2 summarizes the data for the three
specimens tested. In all cases, the CD123+ cells were capable

of engrafting the NOD/SCID animals. Moreover, in all but
one instance, the CD123— populations did not contribute to in

vivo repopulation. Thus, as de?ned by the NOD/SCID model,

(<1%). In contrast, primary AML cells (FIG. 1B) displayed

we conclude that CD123 is expressed on the LSC.
Finally, as an independent means of con?rming the leuke

high levels of CD123. In both the overall CD34+ population,
as well as the more primitive CD34+/CD38— compartment,

mic origin of CD123 positive cells, ?ow cytometry was used

greater than 99% of the cells were positive for CD123. FIG. 2
shows ?ve additional examples of CD123 labeling on

to sort CD34+/CD123+ cells from two leukemic specimens.

These samples were cultured for four days, synchronized and
then harvested for cytogenetic analysis. Examination of
spreads from each specimen showed that 20 out of 20
metaphases was positive for the leukemia-speci?c transloca

CD34+/CD38— AML cells, further demonstrating the strong
expression of this antigen on leukemic populations. Table 1
summarizes the experiments performed to date on the AML
cell type, and shows CD123 levels for primitive cells ofAML

20

tion.

subtypes M1, M2, and M4. Of the 18 primary AML speci
mens examined, CD123 was strongly expressed on the primi
tive leukemia cells in all but two instances. The two samples
which had lower CD123 levels (samples AML-11 and AML
14, Table I) both displayed a uniform shift in CD123 expres
sion, but had an overall labeling intensity that was dimmer
than most samples assayed. In many cases (9 of 18), CD123
negative cells were virtually undetectable (0% or less than
1%). Conversely, expression of CD123 was not detected on 3
of 5 normal samples of CD34+/CD38— cells and was barely
detectable in two additional specimens (<1%). These ?ow

Example 7
Biological Role of CD123 Expression in Leukemia
Cells
25

To further corroborate the data obtained by ?ow cytometry,
immunoblot studies were performed to analyze IL-3R signal
transduction components. For these studies, each AML
sample was derived from a peripheral blood specimen and
30

virtually pure leukemic sample. First, expression of both the

cytometric analyses were con?rmed using two different anti

IL-3R0t and [3 chains were examined. With respect to CD123,
the data shown in FIG. 4 (top panel) clearly demonstrate
expression in all leukemic samples assayed. The CD34+ cells

CD123 monoclonal antibodies to insure that the results were
not an artifact caused by the use of a particular antibody.

The high level of CD123 expression found on all AML

subtypes examined implies that IL-3RO. might play a central

35

on the AML specimens. Interestingly, while some expression
was seen in bulk AML populations, in 15 of 15 specimens
CD131 was never detected in the CD34+ compartment (data

not shown).
Further data demonstrating CD123 expression in primary
ALL and primary CML cells, as well as non-Hodgkin’s lym
phoma, are discussed in Examples 8 and 10.

derived from normal marrow (lane 2, CD34+) also show a
weak signal. This is consistent with the data in FIG. 1A,
which show that normal CD34+ cells often contain a small
subset of CD123+ cells. However, CD123 expression was not

role in creating or maintaining the leukemic state. To form the

high af?nity receptor for IL-3, both the 0t and [3 chains
(CD123 and CD131 respectively) are necessary. Thus,
expression of CD131 was also examined by ?ow cytometry

was sorted to isolate the CD34+ population, thus insuring a

40

detected by ?ow cytometry in the more primitive CD34+/
CD38— subset of normal cells (FIG. 1A and Table 1). Due to
their low frequency, it was not possible to obtain suf?cient
CD34+/CD38— cells of either normal or AML origin for

45

Example 6

direct analysis by immunoblot. Nonetheless, detection of a
clear signal in the overall CD34+ population corroborates the
strong signal seen by ?ow cytometry for AML cells. Another
point to note is that the molecular weight of the CD123 band
appears to vary slightly between AML samples. We have
performed RT-PCR ?ngerprint analyses of the same speci
mens and seen no obvious aberrancies (data not shown).

Thus, it appears that varying degrees of post-translational
In Vivo Engraftment Properties of Human CD123+

50

Leukemia Cells in NOD/SCID Mice

panel).

Given the strong CD123 expression observed on the vast

majority of cells that phenotypically encompass the LSC
population, it appeared likely that CD123 would be useful as
a marker of LSC’s. Therefore, to establish the functional

To begin exploring a potential functional role for CD123,
55

capacity of CD123+ cells, transplantation studies using the
NOD/SCID mouse model system were performed. Three pri
mary AML specimens (AML-2, 5, and 15 from Table 1) were
60

addition, the remaining cells in the population (CD34—/
CD123 +/—) were also sorted and transplanted in parallel. The
data in FIG. 3 are a representative example of one specimen
that showed strong engraftment of leukemic cells at six weeks
post-engraftment. Panel A shows total bone marrow cells
labeled with antibodies speci?c to human CD34 and CD45.

The ?ow cytometric pro?le clearly indicates that a large

we examined the response of primary AML cells to IL-3.

Typically, stimulation of hematopoietic cells with IL-3 leads
to several well-characterized intracellular signal transduction
events (Hara T, et al., Function and signal transduction medi

ated by the interleukin 3 receptor system in hematopoiesis.

assayed by ?ow cytometrically sorting CD34+/CD123+ cells
and transplanting them into irradiated NOD/SCID mice. In

modi?cation are the most likely explanation for this observa
tion. Consistent with the results obtained by ?ow cytometry,
expression of CD131 was not detected (FIG. 4, bottom

65

Stem Cells 1996, 14: 605-18). Prevalent among these events

are phosphorylation of Mek-1, Akt, and Stat-5 (Songyang Z,
et al., Interleukin 3-dependent survival by the Akt protein
kinase. Proc Natl Acad Sci USA 1997, 94: 11345-50; Yag
isawa M, et al., Signal transduction pathways in normal
human monocytes stimulated by cytokines and mediators:
comparative study with normal human neutrophils or trans
formed cells and the putative roles in functionality and cell
biology. Exp Hematol 1999, 27: 1063-76; Sutor S L, et al., A
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phosphatidylinositol 3 -kinase-dependent pathway that differ

Those skilled in the art will recognize, or be able to ascer
tain using no more than routine experimentation, many

entially regulates c-Raf and A-Raf. J Biol Chem 1999, 274:
7002-10; de Groot R P, et al., Regulation of proliferation,

tor family. Cell Signal 1998, 10: 619-28). Consequently,

equivalents to the speci?c embodiments of the invention spe
ci?cally described herein. Such equivalents are intended to be
encompassed in the scope of the following claims.

immunoblot studies were performed on these proteins to
assess the degree of phosphorylation, both in the presence or

TABLE 1

differentiation and survival by the lL-3/lL-5/GM-CSF recep

the absence of lL-3 stimulation. The data, shown in FIG. 5,
show no detectable phosphorylation of Akt and Stat5 in the
absence of lL-3, and only a moderate level of phosphorylation
for Mek-l. Furthermore, in response to lL-3 stimulation, no
appreciable increase in phosphorylation is seen for any of the

Expression of CD123 in Primitive Leukemic and Normal Cells.
% CD123+ cells in

Specimen

proteins assayed. These results suggest that CD123 present

FAB

CD34+/ CD3 8— population

AML

on the surface of primary AML cells does not contribute

signi?cantly to signal transduction via conventional lL-3

mediated pathways.
Example 8
CD123 Expression in Primary ALL and Primary

20

CML Cells

Similar experimental protocol as described in Examples 1
through 4 were followed, and the expression of CD123 was

assayed in primary ALL and primary CML cells by ?ow

25

cytometry. The results were consistent with the results

obtained with expression of CD123 in primary AML in
Example 5. FIGS. 6A, 6B, and 6C show reproducibly that the
primary ALL cells express CD123. Moreover, FIGS. 7A, 7B,
and 7C show reproducibly that the primary CML cells also

30

express CD123.

Example 9

CD123 Targeted Complement-Kill Assay

35

By using a complement-kill assay, “Current protocols in
Immunology” Edited by John Coligan, Ada Kruisbeek, David
Margulies, Ethan Shevach, and Warren Strober, John Wiley
and Sons publishing, 1992, which is incorporated by refer

AML-1
AML-2
AML-3
AML-4
AML-5
AML-6
AML-7
AML-8
AML-9
AML- 10
AML-11
AML- 12
AML- 13
AML- 14
AML- 15
AML-16
AML- 17
AML-18
Normal Marrow

MDS/AML
M1
M1
M4
M2
M4
nd
M4
M4
M2
MDS/AML
nd
M1
M4
M4
M1
M1
M4

BM—l

na

BM—2

na

BM—3

na

BM—4

na

BM—5

na

0
<1 %
0
0

<1 %

FAB = French, American, British classi?cation system

MDS/AML = myelodysplastic syndrome progressing to AML
na = not applicable

ence herein in its entirety, this experiment demonstrates that
CD123+ cells are preferentially targeted. In this experiment,
we compared a typical AML specimen (i.e. CD123+) to a

TABLE 2

normal bone marrow sample. For each specimen there is an

Engra?ment ofCD123+ Populations in NOD/SCID Mice.

untreated control, a sample treated with complement alone,
and a sample treated with anti-CD123+ complement. As
shown in Table 3, there is a substantial complement-killing

100%
100%
95.2%
98.1%
99.7%
99.5%
100%
99.7%
99.8%
100%
70.2%
92.5%
97 .5 %
51.1%
98.1%
95 .3 %
98.9%
100%
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Population

Exp. Specimen Assayed (N)

effect on the AML specimen, but no effect on the normal
marrow. This is true for both the overall sample, as well as the

1

AML-2

Cells

CD34+/CD123+ (3)

4.9 x 10e6

CD34—/CD123+/— (3)

7.5 x 10e5

CD34+/CD123+ (4)

2.5 x 10e6

CD34—/CD123+/— (3)

2.5 x 10e6

CD34+/CD123+ (5)

2.1 x 10e6

CD34—/CD123+/— (3)

2.4 x 10e6

more primitive CD34+ cells. Accordingly, this experiment
demonstrates that there is a difference between the effect on

50

normal and leukemic cells with respect to the speci?city for
CD123.

2

AML-5

Example 10
CD123 Expression in Lymphoma Cells

55

lmmunohistochemical analysis of tissue sections showed

3

that “diffuse large B cell lymphoma” is strongly positive for

AML-15

expression of CD123. This is the most common form of

non-Hodgkin’s lymphoma. Thus, in a B-cell derived cancer,
expression of CD123 is consistent with the observation that
CD123 was also observed onALL cells (i.e. another type of B
cell cancer). This observation directly identi?es B cell lym
phomas as a target for therapies and diagnostics using

60

CD123.

65 N = number ofmice assayed

All of the cited references are incorporated by reference
herein in their entirety.

nd = not detectable

% CD45+

Inj./mouse cells/recip.
42%
18%
67%
nd
0.2%
0.1%
15%
6%
1%
12%
nd
nd
nd
2.1%
0.2%
0.8%
1.1%
0.9%
nd
nd
nd

